102 related articles for article (PubMed ID: 19227559)
21. Virological and immunological response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia.
Jallow S; Kaye S; Alabi A; Aveika A; Sarge-Njie R; Sabally S; Corrah T; Whittle H; Vanham G; Rowland-Jones S; Janssens W; McConkey SJ
AIDS; 2006 Jun; 20(10):1455-8. PubMed ID: 16791023
[No Abstract] [Full Text] [Related]
22. Trial will evaluate a once-daily dose of raltegravir.
AIDS Patient Care STDS; 2008 Nov; 22(11):918-9. PubMed ID: 19043842
[No Abstract] [Full Text] [Related]
23. FDA notifications. Lamivudine/zidovudine combination approved for pediatric use.
AIDS Alert; 2009 Sep; 24(9):105. PubMed ID: 19938311
[No Abstract] [Full Text] [Related]
24. HIV/AIDS clinical trials. A powerful and perplexing new HIV prevention tool.
Cohen J
Science; 2010 Dec; 330(6009):1298-9. PubMed ID: 21127220
[No Abstract] [Full Text] [Related]
25. In brief: Truvada for HIV prevention.
Med Lett Drugs Ther; 2012 Aug; 54(1396):63-4. PubMed ID: 22869292
[No Abstract] [Full Text] [Related]
26. Truvada for HIV prophylaxis in heterosexual patients.
DeDea L
JAAPA; 2012 Oct; 25(10):14. PubMed ID: 23115862
[No Abstract] [Full Text] [Related]
27. FDA approves first drug to prevent HIV infection.
Roehr B
BMJ; 2012 Jul; 345():e4879. PubMed ID: 22807165
[No Abstract] [Full Text] [Related]
28. HIV prevention trial in women is abandoned after drugs show no impact on infection rates.
Roehr B
BMJ; 2011 Apr; 342():d2613. PubMed ID: 21508055
[No Abstract] [Full Text] [Related]
29. HIV pre-exposure prophylaxis.
Morin SF; Yamey G; Rutherford GW
BMJ; 2012 Aug; 345():e5412. PubMed ID: 22890030
[No Abstract] [Full Text] [Related]
30. Mexico conference considers pre-exposure prophylaxis for AIDS.
Roehr B
BMJ; 2008 Aug; 337():a1278. PubMed ID: 18703652
[No Abstract] [Full Text] [Related]
31. PrEP'ing.
Vázquez E
Posit Aware; 2012; 24(5):34-8. PubMed ID: 23091881
[No Abstract] [Full Text] [Related]
32. More pre-exposure prophylaxis for rising HIV infection?
Barreiro P
AIDS Rev; 2014; 16(2):118-9. PubMed ID: 24984768
[No Abstract] [Full Text] [Related]
33. Resistance to antiretrovirals in HIV-infected pregnant women.
Weinberg A; Forster-Harwood J; McFarland EJ; Pappas J; Davies JK; Kinzie K; Barr EA; Paul SM; Salbenblatt CR; Soda E; Vazquez A; Levin MJ
J Clin Virol; 2009 May; 45(1):39-42. PubMed ID: 19329355
[TBL] [Abstract][Full Text] [Related]
34. FDA notifications. FDA approval for generic lamivudine/zidovudine.
AIDS Alert; 2008 Jan; 23(1):12. PubMed ID: 18572476
[No Abstract] [Full Text] [Related]
35. A pill to prevent HIV.
Sandler C
Posit Aware; 2013; 25(1):35-8. PubMed ID: 23646409
[No Abstract] [Full Text] [Related]
36. HIV postexposure prophylaxis after sexual assault: why is it so hard to accomplish?
Cohen MS
Sex Transm Dis; 2008 Dec; 35(12):979-80. PubMed ID: 18955917
[No Abstract] [Full Text] [Related]
37. Facial and limb fat loss: lipoatrophy.
Proj Inf Perspect; 2003 Oct; (36):11-2. PubMed ID: 14696569
[TBL] [Abstract][Full Text] [Related]
38. [Should pre-exposure prophylaxis be used to prevent HIV?].
Nau JY
Rev Med Suisse; 2015 Mar; 11(465):622-3. PubMed ID: 25946876
[No Abstract] [Full Text] [Related]
39. HIV drug-prevention strategy carries risks.
Hayden EC
Nature; 2011 Aug; 476(7360):260-1. PubMed ID: 21850077
[No Abstract] [Full Text] [Related]
40. The iPrEx results: lifting hopes, raising questions.
Auerbach JD
BETA; 2010; 22(4):47-9. PubMed ID: 21591604
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
